The second quarter brings updates for Scholar Rock, Alnylam and Dicerna, among others.
Early 2021 will see rare diseases dominate for biotech, with Sarepta revealing key data on its gene therapy play.
Genmab cans its antibody-drug conjugate against Axl kinase, an approach on which Bergenbio has gone all in.
After a brief pause in the first quarter flotations have come flooding back, with drug developers raising almost $5bn so far this year.
The biotech financing scene in Europe continues to be dwarfed by the US, but on some measures the region is on an even footing.